Generation of induced pluripotent stem cell line (TMOi001-A-11) carrying a homozygous deletion in the synemin gene using CRISPR/Cas9

Stem Cell Res. 2023 Dec:73:103254. doi: 10.1016/j.scr.2023.103254. Epub 2023 Nov 22.

Abstract

A number of genetic variants in the SYNM gene encoding for the intermediate filament synemin have been reported in patients with cardiomyopathies, skeletal myopathies, cancer and certain neurodegenerative disorders. To better understand its role, we generated a human induced pluripotent stem cell line with a homozygous deletion in the SYNM gene by CRISPR/Cas9 genome editing. The synemin-knockout human induced pluripotent stem cells exhibit typical morphology of pluripotent cells, expression of pluripotency markers, normal karyotype and differentiation capacity in the three germ layers. This line will allow us to investigate the role of synemin in cardiomyopathy upon differentiation into beating cardiomyocytes.

MeSH terms

  • CRISPR-Cas Systems / genetics
  • Cardiomyopathies* / genetics
  • Cardiomyopathies* / metabolism
  • Homozygote
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Sequence Deletion

Substances

  • desmuslin